Key statistics
On Monday, Innate Pharma SA (IPH:PAR) closed at 1.94, 45.65% above the 52 week low of 1.33 set on Dec 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.03 |
---|---|
High | 2.03 |
Low | 1.92 |
Bid | 1.94 |
Offer | 1.99 |
Previous close | 2.03 |
Average volume | 193.21k |
---|---|
Shares outstanding | 83.83m |
Free float | 63.56m |
P/E (TTM) | -- |
Market cap | 170.18m EUR |
EPS (TTM) | -0.4215 EUR |
Data delayed at least 15 minutes, as of Mar 10 2025 16:35 BST.
More ▼
- Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
- Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
- Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
- Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
- Innate Pharma Announces Transformative Strategy to Accelerate Growth
- Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
More ▼